Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19079070 | FORMULATIONS OF VIMSELTINIB | March 2025 | May 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19018702 | ILOPROST COMPOSITIONS AND FORMULATIONS THEREOF | January 2025 | July 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18832248 | GINGERENONE A PRODRUGS AS SENSOTHERAPEUTICS AND METHODS OF USE | July 2024 | April 2025 | Allow | 8 | 0 | 1 | Yes | No |
| 18656519 | TREATMENT OF ADENOVIRUS INFECTION OR DISEASE ASSOCIATED WITH ADENOVIRUS INFECTION | May 2024 | March 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18616046 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | March 2024 | November 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18409952 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY, SEIZURES AND OTHER CONDITIONS | January 2024 | February 2025 | Allow | 14 | 0 | 0 | Yes | No |
| 18502589 | COMPOSITIONS AND USES THEREOF FOR TREATMENT OF IDIOPATHIC PRETERM BIRTH | November 2023 | June 2025 | Allow | 20 | 0 | 0 | No | No |
| 18502240 | TREATING IRON DEFICIENCY WITH FERRIC CARBOXYMALTOSE | November 2023 | September 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18474535 | STABLE ORAL SUSPENSIONS OF BACLOFEN | September 2023 | March 2025 | Allow | 17 | 0 | 0 | Yes | No |
| 18231035 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING CALCIPHYLAXIS | August 2023 | June 2025 | Allow | 22 | 1 | 0 | No | No |
| 18346721 | COMPOSITIONS AND METHODS OF USING PROPYLENE SULFIDE-BASED POLYMERS FOR TREATMENT OF CHAGAS DISEASE | July 2023 | January 2025 | Allow | 19 | 0 | 0 | Yes | No |
| 18215989 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING TISSUE CALCIFICATION | June 2023 | March 2025 | Allow | 20 | 0 | 0 | Yes | No |
| 18321968 | COMPOSITIONS AND METHODS FOR REDUCING LAMINITIS OF AN ANIMAL HOOF | May 2023 | April 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18311846 | PHARMACEUTICAL COMBINATION, COMPOSITION AND COMPOUND PREPARATION CONTAINING GLUCOKINASE ACTIVATOR AND K-ATP CHANNEL BLOCKER, PREPARATION METHOD THEREFOR AND USE THEREOF | May 2023 | April 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18142308 | METHODS AND COMPOSITIONS TO TREAT CANCER | May 2023 | January 2025 | Allow | 21 | 1 | 0 | No | No |
| 18138306 | MODULATORS OF GTPASES AND THEIR USE | April 2023 | March 2025 | Allow | 23 | 1 | 0 | No | No |
| 18123702 | METHOD FOR THERAPEUTIC TREATMENT OF ROSACEA | March 2023 | January 2025 | Allow | 22 | 0 | 0 | Yes | No |
| 18173865 | Patentiflorin A Analogs as Antiviral Agents | February 2023 | February 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18077931 | Threonate Compounds and Methods of Use Thereof | December 2022 | May 2025 | Abandon | 30 | 1 | 0 | No | No |
| 18056804 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | November 2022 | June 2025 | Abandon | 31 | 1 | 0 | No | No |
| 18046916 | COMPOSITIONS AND METHODS FOR REDUCING SKIN FAT | October 2022 | December 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 18046917 | COMPOSITIONS AND METHODS FOR CONTROLLING FOOD INTAKE OF ANIMAL | October 2022 | December 2024 | Allow | 26 | 1 | 0 | Yes | No |
| 17798502 | TREATMENT AND PREVENTION OF CAPILLARY MALFORMATION-ARTERIOVENOUS MALFORMATION | August 2022 | June 2025 | Allow | 34 | 1 | 0 | No | No |
| 17788146 | MANAGING MICROBIAL DYSBIOSIS WITH TEMOCILLIN | June 2022 | April 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17743388 | METHOD OF PREPARING NANOPARTICLES COMPRISING POORLY WATER SOLUBLE DRUGS FOR TREATING HEPATITIS | May 2022 | April 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17713746 | PHARMACEUTICAL COMPOSITION FOR TOPICAL WOUND TREATMENT | April 2022 | December 2024 | Allow | 32 | 0 | 1 | Yes | No |
| 17642287 | AGENT FOR PROTECTION OF BLOOD BRAIN SPINAL CORD BARRIER | March 2022 | February 2025 | Allow | 35 | 1 | 1 | Yes | No |
| 17632543 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF THEIR USE IN REVERSING CANCER CHEMORESISTANCE | February 2022 | February 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17578780 | Methods for Treating Ascites | January 2022 | February 2024 | Abandon | 25 | 2 | 0 | Yes | No |
| 17576623 | Cancer Treatment Targeted to Tumor Adaptive Responses to Protein Synthesis Stress | January 2022 | June 2025 | Allow | 41 | 2 | 1 | Yes | No |
| 17558169 | THERAPY AND PREVENTION OF PRION PROTEIN COMPLEX INFECTIONS IN NON-HUMAN ANIMALS | December 2021 | March 2025 | Allow | 39 | 0 | 0 | Yes | No |
| 17528017 | Methods of Treating Prostate Cancer | November 2021 | March 2025 | Allow | 40 | 1 | 0 | No | No |
| 17524304 | METHODS OF REGULATING OXIDOREDUCTASE ACTIVITY FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). | November 2021 | March 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17489349 | COMPOSITIONS AND METHODS FOR PAIN RELIEF AND NUMBING | September 2021 | October 2024 | Abandon | 37 | 3 | 1 | No | No |
| 17255414 | METHODS AND USES OF COLCHICINE DERIVATIVES | December 2020 | February 2025 | Allow | 50 | 3 | 1 | Yes | No |
| 16462317 | PYRIDONE DERIVATIVE PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF | May 2019 | March 2020 | Allow | 10 | 1 | 0 | No | No |
| 16370681 | CROMOLYN COMPOSITIONS FOR TREATMENT OF PULMONARY FIBROSIS | March 2019 | October 2019 | Allow | 6 | 1 | 0 | No | No |
| 16370677 | CROMOLYN COMPOSITIONS FOR TREATMENT OF PULMONARY FIBROSIS | March 2019 | October 2019 | Allow | 7 | 1 | 1 | No | No |
| 16360139 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS IN THE TREATMENT OF NEOPLASMS | March 2019 | June 2020 | Allow | 15 | 1 | 0 | Yes | No |
| 16284461 | COMPOSITIONS AND METHODS OF USE OF PHORBOLESTERS | February 2019 | May 2020 | Allow | 14 | 1 | 0 | No | No |
| 16136920 | PHARMACEUTICAL COMPOSITION CONTAINING CELECOXIB | September 2018 | August 2019 | Allow | 11 | 1 | 0 | No | No |
| 15778747 | Beta-Hydroxyketones as topical active ingredients for the prevention or treatment of photodermatoses | May 2018 | January 2020 | Allow | 20 | 2 | 1 | Yes | No |
| 15890927 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | February 2018 | June 2020 | Allow | 28 | 2 | 1 | No | No |
| 15548345 | STABLE TRIENTINE FORMULATIONS | August 2017 | March 2020 | Allow | 32 | 2 | 0 | No | Yes |
| 14297671 | METHODS AND COMPOSITIONS FOR LOCALLY INCREASING BODY FAT | June 2014 | September 2014 | Allow | 3 | 1 | 0 | No | No |
| 14086785 | METHODS AND COMPOSITIONS FOR LOCALLY INCREASING BODY FAT | November 2013 | May 2014 | Allow | 6 | 0 | 0 | Yes | No |
| 13860234 | Method for Enhancing Sports Scores | April 2013 | January 2014 | Allow | 10 | 0 | 1 | No | No |
| 13607489 | Topical Itraconazole Formulations and Uses Thereof | September 2012 | February 2015 | Allow | 30 | 1 | 1 | Yes | No |
| 13553453 | METHODS AND COMPOSITIONS COMPRISING AT LEAST ONE ALPHA3 BETA4 nAChR ANTAGONIST OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | July 2012 | January 2015 | Allow | 30 | 2 | 1 | Yes | No |
| 13533131 | Methods of Treatment Using Allosteric Processing Inhibitors for Matrix Metalloproteinases | June 2012 | July 2014 | Allow | 25 | 2 | 1 | No | No |
| 13442018 | ANTIMICROBIAL COMPOSITIONS AND RELATED METHODS | April 2012 | April 2013 | Allow | 13 | 0 | 0 | No | No |
| 13500241 | COMBINATION | April 2012 | May 2014 | Allow | 25 | 2 | 1 | Yes | No |
| 13322842 | METHODS AND COMPOSITIONS FOR TREATING NEOPLASIA | March 2012 | April 2013 | Allow | 16 | 1 | 1 | Yes | No |
| 13407251 | SULFONAMIDES AS TRPM8 MODULATORS | February 2012 | March 2014 | Allow | 25 | 2 | 1 | Yes | No |
| 11915148 | PYRIMIDINE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | December 2011 | June 2011 | Allow | 42 | 2 | 1 | No | No |
| 13255550 | METHOD FOR PREDICTING THERAPEUTIC EFFICACY OF CHEMOTHERAPY ON NON-SMALL-CELL LUNG CANCER | November 2011 | August 2013 | Allow | 23 | 1 | 1 | No | No |
| 13259632 | Cosmetic Composition Containing Calcium Citrate And N-Acylated Aminoalcohol Derivative To Prevent Dry Skin And Signs Of Cutaneous Ageing | September 2011 | July 2013 | Allow | 22 | 1 | 1 | Yes | No |
| 13256127 | SODIUM SALT OF 5-CYCLOPROPYL-2-{[2-(2,6-DIFLUOROPHENYL)PYRIMIDIN-5-YL]AMINO}BENZOIC ACID AS DHODH INHIBITOR | September 2011 | April 2013 | Allow | 20 | 1 | 1 | Yes | No |
| 13119733 | USE OF AZAPERONE FOR IMPROVING GROWTH PERFORMANCE | March 2011 | May 2013 | Allow | 26 | 2 | 0 | No | Yes |
| 12958210 | METHODS AND COMPOSITIONS | December 2010 | May 2012 | Allow | 18 | 1 | 0 | Yes | No |
| 12892671 | LINOLEIC PHOSPHOLIPIDS AND USES THEREOF FOR INHIBITING INFLAMMATORY AND NEURODEGENERATIVE PROCESSES | September 2010 | August 2014 | Allow | 46 | 2 | 1 | No | No |
| 12879483 | PREPARATION OF THE FORMAURINDIKARBOXYL ACID BASE AND ITS DERIVATIONS AND USE | September 2010 | August 2011 | Allow | 11 | 1 | 0 | Yes | No |
| 12854033 | METHOD AND COMPOSITION FOR TREATING NODULOCYSTIC AND CONGLOBATE ACNE VULGARIS | August 2010 | September 2013 | Allow | 37 | 2 | 0 | No | Yes |
| 12776759 | DITERPENE MODULATOR OF MACROPHAGE PHAGOSOMAL MATURATION | May 2010 | June 2012 | Allow | 26 | 0 | 1 | Yes | No |
| 12757420 | USE OF TETRAHYDROBIOPTERIN AS A MARKER AND A THERAPEUTIC AGENT FOR FABRY DISEASE | April 2010 | November 2012 | Allow | 32 | 1 | 1 | No | No |
| 12679523 | TERNARY FUNGICIDAL COMPOSITIONS COMPRISING BOSCALID AND CHLOROTHALONIL | March 2010 | September 2012 | Allow | 30 | 1 | 1 | Yes | No |
| 12710203 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | February 2010 | March 2013 | Allow | 37 | 1 | 1 | No | No |
| 12656992 | Iminosugars and methods of treating viral diseases | February 2010 | January 2013 | Allow | 35 | 2 | 1 | Yes | Yes |
| 12525503 | NOVEL INDOLIC DERIVATIVES, THEIR PREPARATION PROCESSES AND THEIR USES IN PARTICULAR AS ANTIBACTERIALS | February 2010 | October 2012 | Allow | 38 | 2 | 1 | No | No |
| 12672347 | GALACTOKINASE INHIBITORS | February 2010 | July 2012 | Allow | 30 | 1 | 1 | Yes | No |
| 12693252 | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES | January 2010 | February 2012 | Allow | 24 | 1 | 1 | No | No |
| 12664237 | METHODS FOR TREATMENT FOR ULCERATIVE COLITIS IN MAMMALS | December 2009 | March 2013 | Allow | 39 | 2 | 1 | Yes | No |
| 12550291 | METHODS OF USING CRYSTALLINE FORMS OF A SALT OF A FACTOR XA INHIBITOR | August 2009 | February 2013 | Allow | 42 | 3 | 1 | Yes | No |
| 12306333 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | August 2009 | August 2012 | Allow | 44 | 0 | 1 | Yes | No |
| 12491988 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF | June 2009 | April 2012 | Allow | 34 | 1 | 1 | Yes | No |
| 10560676 | SIR2 REGULATION | June 2009 | January 2013 | Allow | 60 | 3 | 1 | No | No |
| 12301381 | COMPOSITION FOR INACTIVATING AN ENVELOPED VIRUS | June 2009 | July 2014 | Allow | 60 | 2 | 1 | Yes | No |
| 11992211 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DRUG OR ALCOHOL ADDICTION OR BIPOLAR DISORDER USING SODIUM PHENYLBUTYRATE | February 2009 | April 2011 | Allow | 37 | 2 | 0 | Yes | No |
| 12158001 | LONG TERM WEIGHT MAINTENANCE | October 2008 | July 2012 | Allow | 49 | 2 | 1 | No | No |
| 11885039 | CRYSTALLINE FORMS OF (1RS,3RS,6RS)-6-DIMETHYLAMINOMETHYL-1-(3-METHOXYPHENYL)CYCLOHEXANE-1,3-DIOL HYDROCHLORIDE | June 2008 | August 2012 | Allow | 60 | 1 | 2 | Yes | No |
| 12103783 | PREPARATION OF THE FORMAURINDICARBOXYLIC ACID BASE AND ITS DERIVATIONS AND USE | April 2008 | May 2011 | Allow | 37 | 2 | 1 | No | No |
| 12101690 | COMPOUNDS FOR MODULATING T-CELLS | April 2008 | May 2011 | Allow | 37 | 1 | 1 | Yes | No |
| 11908019 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | April 2008 | March 2014 | Allow | 60 | 2 | 1 | No | Yes |
| 11887989 | PROTECTIVE AGENT FOR RETINAL NEURONAL CELL COMPRISING INDAZOLE DERIVATIVE AS ACTIVE INGREDIENT | October 2007 | April 2012 | Allow | 54 | 3 | 0 | No | No |
| 11832834 | APPLICATIONS OF THE BINDING INTERACTION OF PROANTHOCYANIDINS WITH BACTERIA AND BACTERIAL COMPONENTS | August 2007 | February 2014 | Allow | 60 | 3 | 1 | Yes | No |
| 11660351 | USE OF A PDE 5 INHIBITOR FOR TREATING AND PREVENTING HYPOPIGMENTARY DISORDERS | July 2007 | May 2012 | Allow | 60 | 2 | 1 | Yes | No |
| 10574438 | ANALGESIC METHODS AND COMPOSITIONS | June 2007 | August 2012 | Allow | 60 | 9 | 0 | Yes | No |
| 10585609 | USE OF SUBSTITUTED 2-AMINOTETRALINS FOR PREVENTIVE TREATMENT OF PARKINSON'S DISEASE | March 2007 | June 2012 | Allow | 60 | 4 | 1 | Yes | No |
| 11526853 | METHOD FOR THE TREATMENT OF ANTHRAX INFECTIONS | September 2006 | April 2012 | Allow | 60 | 3 | 1 | Yes | No |
| 11497870 | METHODS AND COMPOSITIONS FOR REDUCING SKIN DAMAGE | July 2006 | September 2011 | Allow | 60 | 1 | 0 | Yes | No |
| 10902471 | ANTI-HIV ACTIVITY OF THE OPIOID ANTAGONIST NALOXONE | July 2004 | June 2011 | Allow | 60 | 6 | 1 | Yes | No |
| 10143388 | ANTIBACTERIAL DENTIFRICE EXHIBITING ENHANCED ANTIPLAQUE AND BREATH FRESHENING PROPERTIES | May 2002 | October 2011 | Allow | 60 | 11 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RAO, SAVITHA M.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 60.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner RAO, SAVITHA M works in Art Unit 1691 and has examined 86 patent applications in our dataset. With an allowance rate of 91.9%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner RAO, SAVITHA M's allowance rate of 91.9% places them in the 76% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by RAO, SAVITHA M receive 1.57 office actions before reaching final disposition. This places the examiner in the 40% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by RAO, SAVITHA M is 30 months. This places the examiner in the 39% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +14.2% benefit to allowance rate for applications examined by RAO, SAVITHA M. This interview benefit is in the 56% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 36.2% of applications are subsequently allowed. This success rate is in the 78% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 63.6% of cases where such amendments are filed. This entry rate is in the 85% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 83.3% of appeals filed. This is in the 73% percentile among all examiners. Of these withdrawals, 60.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 50.0% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.2% of allowed cases (in the 70% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.